🔗 Share this article

As America undertakes historic adjustments to its immunization recommendations, a particular individual appears unexpectedly: Høeg, a Danish American physician and epidemiologist who rose to prominence by questioning COVID-19 shots throughout the pandemic and has concentrated on alleged deaths after Covid immunization in her recent position at the FDA.

Proposed Shifts to Childhood Vaccine Schedule

Public health authorities planned to unveil major changes to the pediatric vaccination calendar recently, synchronizing the US with the Danish national calendar, it is understood – a major change that would place the US at odds with many the international standard with no evidence for public health gain. This reveal has been pushed back until the coming year.

In place of Vinay Prasad, Dr. Høeg is scheduled to address the audience at the gathering. She was recently named temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to head the center this calendar year.

A New Direction at the Agency

The acting appointment could signify a strengthened alliance between the drug and vaccine divisions as Høeg and Dr. Prasad strengthen their influence at the agency – and it points to a increased emphasis upon reevaluating previously authorized immunizations at the FDA.

The new acting director has often pushed for halting specific childhood immunization guidelines in the US so as to align more like Denmark's approach, a nation with universal health coverage and a citizenry roughly the size of Wisconsin’s.

So far comments, she has continued to focus on immunizations – usually the domain of Prasad, director of the FDA’s CBER – rather than drug regulation.

Doubts Over Expertise

The appointee has no obvious background in drug development, approval processes or administrative roles, which has been customary for previous leaders of the Center for Biologics Evaluation and Research. She has served at the FDA as a senior adviser to the FDA chief and CBER since March.

“She doesn’t seem to have the requisite experience” for running the pharmaceutical oversight division, remarked Dr. Jonathan Howard. “She lacks experience running a clinical trial. She lacks experience in running a large organization. She lacks background in drug approvals.”

Former commissioners of CBER would “grasp laws and regulations and the underlying principles of drug development”, commented Janet Woodcock. “Frankly, she lacks the type of experience that prior appointees who ran CBER have had.”

This division has an enormous workload at the agency, the former commissioner pointed out.

“Many people just pays attention on the innovative therapies, but the generic program clears a multitude of generic drugs. There’s a biosimilars program, non-prescription drug unit and so forth, and every single one must be managed,” Woodcock said. “The area you don’t keep your eye on, that is precisely what that I always told people is going to bite you.”

Furthermore, a significant administrative component to the position, which supervises more than 5,000 employees. “It’s a massive leadership role, if you perform it correctly,” Woodcock added.

Response and Contentious Initiatives

In response to concerns about Høeg’s fitness for the role and whether this appointment represents more teamwork among FDA leaders on vaccines, a representative stated that the “inquiries stem from incorrect premises”.

“Her resume is consistent with the responsibilities of her position,” the official explained, pointing to the time Dr. Høeg spent advising the FDA commissioner on “drug safety and regulatory science, including computational safety modeling and vaccine surveillance”.

In her interim role, Dr. Høeg takes over the commissioner’s new fast-track approval initiative, a disputed expedited drug-approval program that reportedly concerned her former heads. “How are these medications being picked for this fast-track system? Who takes the calls?” Howard said. “There’s a lot of secrecy occurring at the regulatory body right now.”

Broadly speaking, he remarked, “the FDA looks to be trending towards more relaxed regulations of most medications, except for shots.”

Established Track Record on Vaccines

Regarding immunizations, Høeg has a more documented, if troubling, past, some experts have noted. She authored a research paper using non-validated public submissions to determine the incidence of heart inflammation following COVID-19 immunization. She counseled the state of Florida top health official Joseph Ladapo, who reportedly have modified findings to imply Covid vaccines are more dangerous than they are.

Among her “policy goals” for the current government encompassed altering rules for new vaccines and halting “optional” immunizations, she remarked post-election on a audio program. At the agency, Dr. Høeg has according to sources suggested barring young men from receiving COVID-19 vaccines.

“She’s an all-around ideologue who starts off with her preconceived notions and works backwards to accommodate the data in a extremely disingenuous, dishonest manner,” Howard argued.

Gaining Influence and a “Push for Payback”

Dr. Høeg aligned with other contrarians, {like|